Biocompare.com RSS feed http://www.biocompare.com/ © 2010 Biocompare.com Sun, 01 Aug 2010 02:46:11 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ BETHESDA, Md., July 29, 2010 - Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer. http://news.biocompare.com/newsstory.asp?id=335980 Biocompare.com Fri, 30 Jul 2010 14:15:00 GMT PITTSBURGH-Researchers at Carnegie Mellon University have developed a new fluorescent biosensor that could aid in the development of an important class of drugs that target a crucial class of proteins called G protein-coupled receptors (GPCRs). http://news.biocompare.com/newsstory.asp?id=335968 Biocompare.com Fri, 30 Jul 2010 13:42:00 GMT A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer, according to new studies by Howard Hughes Medical Institute (HHMI) scientists and their colleagues. http://news.biocompare.com/newsstory.asp?id=335963 Biocompare.com Fri, 30 Jul 2010 13:21:00 GMT Often causing no symptoms in carriers of the disease, worldwide tuberculosis (TB) infects eight to ten million people every year, kills two million, and it is highly contagious as it is spread through coughing and sneezing. "It's a global health disaster waiting to happen, even here in Canada, but this new paradigm in TB research may offer an immediate opportunity to improve vaccination and treatment initiatives," explains Dr. Maziar Divangahi of McGill University and of the Research Institute of the McGill University Health Centre. http://news.biocompare.com/newsstory.asp?id=335960 Biocompare.com Fri, 30 Jul 2010 13:14:00 GMT LA JOLLA, CA - July 28, 2010 - For Immediate Release - A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute. http://news.biocompare.com/newsstory.asp?id=335946 Biocompare.com Fri, 30 Jul 2010 10:57:00 GMT STANFORD, Calif. - Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady. http://news.biocompare.com/newsstory.asp?id=335764 Biocompare.com Thu, 29 Jul 2010 15:01:00 GMT A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease. http://news.biocompare.com/newsstory.asp?id=335762 Biocompare.com Thu, 29 Jul 2010 13:08:00 GMT Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases (MMPs), provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development. Results of the research, from the laboratories of Buck faculty members Lisa Ellerby, Ph.D. and Robert Hughes, Ph.D., appear as the cover story in the July 29, 2010 edition of Neuron. http://news.biocompare.com/newsstory.asp?id=335761 Biocompare.com Thu, 29 Jul 2010 13:07:00 GMT Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction. An article on the topic appears in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. http://news.biocompare.com/newsstory.asp?id=335757 Biocompare.com Thu, 29 Jul 2010 11:58:00 GMT Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML). http://news.biocompare.com/newsstory.asp?id=335750 Biocompare.com Thu, 29 Jul 2010 11:31:00 GMT